SCHEMBL2179283

SCHEMBL2179283

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)cc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
TP53 P04637 2/20 0.51
SDCBP O00560 5/20 0.50
SDC2 P34741 5/20 0.50
THRB P10828 2/20 0.44
DGAT1 O75907 2/20 0.42
KDR P35968 1/20 0.42
EGFR P00533 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179275 1.00 LMNA (0.51) LMNATP53SDCBPSDC2THRB
SCHEMBL2177774 0.93 LMNA (0.45) LMNATP53SDCBPSDC2THRB
SCHEMBL2177768 0.93 LMNA (0.45) LMNATP53SDCBPSDC2THRB
SCHEMBL2179963 0.92 KDR (0.50) LMNATP53SDCBPSDC2DGAT1
SCHEMBL2177490 0.92 KDR (0.50) LMNATP53SDCBPSDC2DGAT1
SCHEMBL2179239 0.92 LMNA (0.53) LMNATP53SDCBPSDC2THRB
SCHEMBL2178235 0.92 LMNA (0.53) LMNATP53SDCBPSDC2THRB
SCHEMBL2181198 0.92 LMNA (0.47) LMNATP53SDCBPSDC2THRB
SCHEMBL2182061 0.92 LMNA (0.47) LMNATP53SDCBPSDC2THRB
SCHEMBL2181226 0.92 LMNA (0.51) LMNATP53SDCBPSDC2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT LMNA 2193/4885TP53 2093/4885SDCBP 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.